Degron Therapeutics secures $40 million Series A Extension to further develop its molecular glue degrader clinical programs, led by LAPAM CAPITAL.
Amount Raised
$40 Million
Round Type
Series A
Investors
Description
Degron Therapeutics has closed a $40 million Series A Extension, bringing its total capital raised to $95 million. The proceeds will support the advancement of clinical programs targeting previously undruggable proteins. The lead program is currently in Phase 1 clinical trials aimed at treating advanced solid tumors. This financing was led by LAPAM CAPITAL with participation from several other investors.
Quick answer
Degron Therapeutics raised $40 Million in a Series A round, dated May 14, 2026. Investors: Cspc & Growth, ApicHope, Gage Capital, Kinghall Ventures, Casstar, Gtja Investment Group, Fortune Capital and GF Xinde.
- How much did Degron Therapeutics raise?
- Degron Therapeutics raised $40 Million in a Series A round on May 14, 2026.
- Who invested in Degron Therapeutics?
- Cspc & Growth, ApicHope, Gage Capital, Kinghall Ventures, Casstar, Gtja Investment Group, Fortune Capital and GF Xinde are named as investors in this round.
- What does Degron Therapeutics do?
- Degron Therapeutics is a biotechnology company advancing human health by developing novel medicines using its robust molecular glue-based targeted protein degradation drug discovery platform.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Degron Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- RedHill Biopharma Ltd raised $6M (Post-IPO Equity) on June 18, 2026.
- OliX Pharmaceuticals raised $89M (Post-IPO Equity) on June 4, 2026.
- Advanced NanoTherapies raised $31M (Series B) on June 2, 2026.
- Psilera raised $8.8M (Seed) on May 28, 2026.
- Maze Therapeutics raised $145M (Post-IPO Equity) on April 22, 2026.
- Ray Therapeutics raised $125M (Series B) on April 21, 2026.
Who to call at Degron Therapeutics, and when
A new round usually means Degron Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Degron Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Degron Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Degron Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Degron Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansDegron Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.